Immunother Limited Company Announces its Participation to IUIS 2019

We are honored to announce the participation of Immunother Ltd. at the world’s leading conference in the field of immunology, IUIS 2019 will offer a unique cross-disciplinary platform for basic, translational and clinical scientists – from those in their early career stages to globally renowned key opinion leaders.

The scientific program will be organized around our core themes:





Our role and goal at IUIS 2019, is to present and promote one of our patents (patent number: 9764015) obtained in India and recognized, since December 2018, by the Chinese Center for Disease Control and Prevention.

The technology in general relates Hemoglobin receptor or its part as a novel vaccine candidate against Leishmaniasis. Specifically, the present invention envisages HbR DNA for eliciting immune response in a mammal against Leishmaniasis. Additional aspect of the present invention is related to a vaccine composition for inducing immune response against Leishmaniasis in mammals. In a preferred aspect, the present invention relates to use of HbR-polypeptide as marker for diagnosis of Leishmania in kala-azar patients.

About Visceral Leishmaniasis (VL), also known as kala-azar, black fever, and Dumdum fever, is the most severe form of Leishmaniasis and, without proper diagnosis and treatment, is associated with high fatality. This disease is the second-largest parasitic killer in the world (after malaria), responsible for an estimated 200,000 to 400,000 infections each year worldwide.

Immunother Limited Company (ISIN: CN1000207834) is a privately held Shenzen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.

Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.